In the therapy regimen, low expression of miR-92b-5p with hormone therapy (HT) had better survival than that without HT (p < 0.001), and high expression of MTSS1L with HT had better survival (p = 0.005) than low expression of MTSS1L with HT (p = 0.01), indicating that MTSS1L may be involved in the survival of breast cancer patients on hormone therapy (Figure 8C). The gene discussed is MTSS2; the disease is breast carcinoma.